Therefore, future in vivo studies should be directed toward evaluating combinatory treatments of HDACis with modulators of CBP/p300 signaling in mouse models of CRC to determine whether tumor/size incidence is reduced compared with treatment with each class of agent in isolation. The gene discussed is EP300; the disease is neoplasm.